{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:27:08Z","timestamp":1790836028102,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.breast.2023.03.007","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T18:28:00Z","timestamp":1679682480000},"page":"312-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Future potential targets of antibody-drug conjugates in breast cancer"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0359-0267","authenticated-orcid":false,"given":"Chiara","family":"Corti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Boscolo Bielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra Carnevale","family":"Schianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice Taurelli","family":"Salimbeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.breast.2023.03.007_bib1","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.3390\/cancers13122898","article-title":"Antibody\u2013drug conjugates for the treatment of breast cancer","volume":"13","author":"Corti","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.breast.2023.03.007_bib2","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.breast.2023.03.007_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2023.03.007_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2022.04.039","article-title":"Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?","volume":"171","author":"Corti","year":"2022","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.breast.2023.03.007_bib5","first-page":"4154","article-title":"Phase I clinical comparative study of monoclonal antibody KS1\/4 and KS1\/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma","volume":"50","author":"Elias","year":"1990","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.breast.2023.03.007_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","article-title":"Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia","volume":"11","author":"Baron","year":"2018","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.breast.2023.03.007_bib7","series-title":"KADCYLA (ado-trastuzumab emtansine), highlights of prescribing information","year":"2021"},{"issue":"19","key":"10.1016\/j.breast.2023.03.007_bib8","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.breast.2023.03.007_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2023.03.007_bib10","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","author":"Tarantino","year":"2021","journal-title":"CA A Cancer J Clin"},{"issue":"7","key":"10.1016\/j.breast.2023.03.007_bib11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.breast.2023.03.007_bib12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"10371","key":"10.1016\/j.breast.2023.03.007_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.breast.2023.03.007_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.breast.2023.03.007_bib15","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.breast.2023.03.007_bib16","article-title":"Abstract GS3-06: biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"81","author":"Hurvitz","year":"2021","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.breast.2023.03.007_bib17","article-title":"Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician\u2019s choice (TPC) in patients (Pts) with hormone receptor\u2013positive\/HER2-negative (HR+\/HER2-) advanced breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Orthod"},{"issue":"suppl 2","key":"10.1016\/j.breast.2023.03.007_bib18","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.annonc.2021.03.213","article-title":"LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody\u2013drug conjugate (ADC), for triple-negative breast cancer (TNBC): preliminary results from an ongoing phase I trial [abstract]","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2023.03.007_bib19","series-title":"PD13-08 phase 1 TROPION-PanTumor01 study evaluating datopotamab deruxtecan (Dato-DXd) in unresectable or metastatic hormone receptor\u2013positive\/HER2\u2013negative breast cancer (BC). 6-10","author":"Meric-Bernstam","year":"2022"},{"key":"10.1016\/j.breast.2023.03.007_bib20","doi-asserted-by":"crossref","DOI":"10.14694\/EdBook_AM.2013.33.e103","article-title":"Picking the optimal target for antibody-drug conjugates","author":"Mathur","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.breast.2023.03.007_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55460-9","article-title":"Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA synthesis","volume":"9","author":"Kedashiro","year":"2019","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.breast.2023.03.007_bib22","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.breast.2023.03.007_bib23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.breast.2023.03.007_bib24","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/annonc\/mdw678","article-title":"Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer","volume":"28","author":"M-Rabet","year":"2017","journal-title":"Ann Oncol"},{"issue":"1\u20132","key":"10.1016\/j.breast.2023.03.007_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cca.2005.05.018","article-title":"Tissue factor and tumor: clinical and laboratory aspects","volume":"364","author":"F\u00f6rster","year":"2006","journal-title":"Clin Chim Acta"},{"issue":"5","key":"10.1016\/j.breast.2023.03.007_bib26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2023.03.007_bib27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-21-1181","article-title":"Phase I\/IIa trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors","volume":"28","author":"Rottey","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.breast.2023.03.007_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2217\/imt.16.4","article-title":"Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy","volume":"8","author":"O'Hara","year":"2016","journal-title":"Immunotherapy"},{"issue":"12","key":"10.1016\/j.breast.2023.03.007_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114900","article-title":"Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival","volume":"9","author":"Tozbikian","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.breast.2023.03.007_bib30","doi-asserted-by":"crossref","unstructured":"Zhao X.Y., Subramanyam B., Sarapa N., et al. Novel antibody therapeutics targeting mesothelin in solid tumors Oct. Clin Cancer Drugs 2016;3(2):76\u201386. doi:10.2174\/2212697X03666160218215744.","DOI":"10.2174\/2212697X03666160218215744"},{"issue":"4","key":"10.1016\/j.breast.2023.03.007_bib31","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","article-title":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","volume":"23","author":"Kindler","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2023.03.007_bib32","first-page":"1","article-title":"Preclinical safety profile of RC88-ADC\uff1aa novel mesothelin-targeted antibody conjugated with Monomethyl auristatin E","author":"Jiang","year":"2021","journal-title":"Drug Chem Toxicol"},{"issue":"7\u20138","key":"10.1016\/j.breast.2023.03.007_bib33","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2119\/2007-00040.Taylor","article-title":"The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer","volume":"13","author":"Taylor","year":"2007","journal-title":"Mol Med"},{"issue":"5","key":"10.1016\/j.breast.2023.03.007_bib34","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0959-8049(94)90543-6","article-title":"Oestrogen-regulated genes in breast cancer: association of pLIV1 with lymph node involvement","volume":"30A","author":"Manning","year":"1994","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.breast.2023.03.007_bib35","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1158\/1535-7163.MCT-13-0896","article-title":"SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer","volume":"13","author":"Sussman","year":"2014","journal-title":"Mol Cancer Therapeut"},{"issue":"13","key":"10.1016\/j.breast.2023.03.007_bib36","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1158\/1538-7445.AM2018-2742","article-title":"Abstract 2742: additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor","volume":"78","author":"Cao","year":"2018","journal-title":"Cancer Res"},{"issue":"4_Supplement","key":"10.1016\/j.breast.2023.03.007_bib37","doi-asserted-by":"crossref","first-page":"PD3","DOI":"10.1158\/1538-7445.SABCS17-PD3-14","article-title":"Abstract PD3-14: phase 1 study of the antibody\u2013drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer","volume":"78","author":"Modi","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2023.03.007_bib38","doi-asserted-by":"crossref","DOI":"10.1007\/s40259-021-00472-z","article-title":"Clinical development of new antibody-drug conjugates in breast cancer: to infinity and beyond","author":"Barroso-Sousa","year":"2021","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.breast.2023.03.007_bib39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody-drug conjugates in solid tumors: a look into novel targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.breast.2023.03.007_bib40","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS17-PD3-14","article-title":"Abstract PD3-14: phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer","volume":"78","author":"Modi","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2023.03.007_bib41","doi-asserted-by":"crossref","first-page":"S474","DOI":"10.1016\/j.annonc.2021.08.542","article-title":"259P Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer","volume":"32","author":"Tsai","year":"2021","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.breast.2023.03.007_bib42","article-title":"SGNLVA-002: single-arm, open label phase Ib\/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer","volume":"37","author":"Han","year":"2019","journal-title":"J Clin Orthod"},{"issue":"suppl_5","key":"10.1016\/j.breast.2023.03.007_bib43","first-page":"S457","article-title":"259P - weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer","volume":"32","author":"Tsai","year":"2021","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.breast.2023.03.007_bib44","article-title":"Phase 1b\/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)","volume":"40","author":"Meisel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2023.03.007_bib45","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00428-016-1911-3","article-title":"Expression of ROR1 has prognostic significance in triple negative breast cancer","volume":"468","author":"Chien","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.breast.2023.03.007_bib46","series-title":"Proceedings of the 105th annual meeting of the American association for cancer research; 2014 apr 5-9; san diego, CA","article-title":"WNT5a\/ROR1 axis in triple-negative breast cancer progression and potential therapy. [abstract]","author":"Borcherding","year":"2014"},{"issue":"15","key":"10.1016\/j.breast.2023.03.007_bib47","article-title":"NBE-002: a novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors - a phase 1\/2 clinical trial","volume":"39","author":"Tolcher","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2023.03.007_bib48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s13046-021-02187-z","article-title":"WNT11\/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer","volume":"40","author":"Menck","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.breast.2023.03.007_bib49","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1002\/jcb.29666","article-title":"ROR2 promotes the epithelial-mesenchymal transition by regulating MAPK\/p38 signaling pathway in breast cancer","volume":"121","author":"Xu","year":"2020","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.breast.2023.03.007_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/msb4100012","article-title":"Phosphotyrosine interactome of the ErbB-receptor kinase family","volume":"1","author":"Schulze","year":"2005","journal-title":"Mol Syst Biol"},{"issue":"7","key":"10.1016\/j.breast.2023.03.007_bib51","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/cgt.2008.15","article-title":"The ERBB3 receptor in cancer and cancer gene therapy","volume":"15","author":"Sithanandam","year":"2008","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/j.breast.2023.03.007_bib52","first-page":"355","article-title":"HER3 signaling and targeted therapy in cancer","volume":"12","author":"Mishra","year":"2018","journal-title":"Onco Rev"},{"issue":"3","key":"10.1016\/j.breast.2023.03.007_bib53","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41388-019-1001-5","article-title":"ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics","volume":"39","author":"Kiavue","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.breast.2023.03.007_bib54","series-title":"Abstract 261 - single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: updated results from a phase I\/II trial","author":"Yonemori","year":"2019"},{"issue":"16_suppl","key":"10.1016\/j.breast.2023.03.007_bib55","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.1002","article-title":"Results from the phase 1\/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)","volume":"40","author":"Krop","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.03.007_bib56","article-title":"Therapeutic vaccines for breast cancer: has the time finally come?","author":"Corti","year":"2021","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.breast.2023.03.007_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004312","article-title":"The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)\/OBI-821 and expression of Globo H in metastatic breast cancer","volume":"10","author":"Hung","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.breast.2023.03.007_bib58","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","article-title":"Exploiting the folate receptor \u03b1 in oncology","volume":"17","author":"Scaranti","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2023.03.007_bib59","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13543784.2022.2054326","article-title":"CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress","volume":"31","author":"Corti","year":"2022","journal-title":"Expet Opin Invest Drugs"},{"issue":"1","key":"10.1016\/j.breast.2023.03.007_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/antib10010006","article-title":"Novel anti-FOLR1 antibody-drug conjugate MORAb-202 in breast cancer and non-small cell lung cancer cells","volume":"10","author":"Matsunaga","year":"2021","journal-title":"Antibodies"},{"issue":"14","key":"10.1016\/j.breast.2023.03.007_bib61","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-20-4740","article-title":"First-in-Human phase 1 study of MORAb-202, an antibody-drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-\u03b1-positive advanced solid tumors","volume":"27","author":"Shimizu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.breast.2023.03.007_bib62","article-title":"First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced\/metastatic solid tumors","volume":"40","author":"Meric-Bernstam","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.03.007_bib63","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41523-018-0095-1","article-title":"Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer","volume":"4","author":"Altan","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.breast.2023.03.007_bib64","article-title":"854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models","author":"Gray","year":"2021","journal-title":"J. Immuno Therapy Cancer"},{"issue":"1","key":"10.1016\/j.breast.2023.03.007_bib65","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.breast.2023.03.007_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/ph14090884","article-title":"Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies","volume":"14","author":"Antonarelli","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.breast.2023.03.007_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102410","article-title":"Artificial intelligence for prediction of treatment outcomes in breast cancer: systematic review of design, reporting standards, and bias","volume":"108","author":"Corti","year":"2022","journal-title":"Cancer Treat Rev"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977623004241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977623004241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:47:11Z","timestamp":1760777231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977623004241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":67,"alternative-id":["S0960977623004241"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2023.03.007","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future potential targets of antibody-drug conjugates in breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2023.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}